

May 21, 2021

The National Stock Exchange of India Limited  
Exchange Plaza  
Bandra Kurla Complex, Bandra (E)  
Mumbai - 400051

The Bombay Stock Exchange Limited  
15<sup>th</sup> Floor, Phiroze Jeejeeboy Towers  
Dalal Street,  
Mumbai – 400001

**Subject: Press Release for Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2021**

Dear Sir/Madam,

Please find enclosed herewith the Press Release for the Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2021.

Thanking You,

For Dr. Lal PathLabs Limited



**Rajat Kalra**  
**Company Secretary and Legal Head**



Encl: As above

**Dr. Lal PathLabs Limited records revenue of Rs 431.0 Cr in Q4 FY 2020-21**

**New Delhi, India, May 21, 2021** – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended March 31, 2021

**Consolidated Performance Highlights: Q4 FY 2020-21 vs Q4 FY 2019-20**
**Revenue: Rs 431.0 Cr, a growth of 42.9%**
**Normalised EBITDA at Rs 129.5 Cr with margin at 30.0%**
**PBT at Rs 110.8 Cr with margin at 25.7%, and**
**PAT Rs 85.1 Cr with margin at 19.7%**

- Operating Revenue increased by 42.9% in Q4 FY21 to Rs. 431.0 Cr vs Rs 301.7 Cr in Q4 FY20
- Covid and Allied contributed 11.2% to Revenue in Q4 FY21 with 4.54 lac RTPCR tests
- Normalised EBITDA (after adjustment for stock based compensation & CSR cost) for Q4 FY21 is at Rs. 129.5 Cr Vs Rs 64.2 Cr in the same quarter last year
- PBT is at Rs 110.8 Cr in Q4 FY21 vs Rs 45.4 Cr. in Q4 last year
- Profit after Tax in Q4 FY21 at Rs. 85.1 Cr as compared to Rs 32.6 Cr in Q4 last year
- Final Dividend of Rs.8 per equity share of Rs. 10 each has been approved by the Board

**Financial Overview (Consolidated) in Rs Cr**

Particulars	Q4 FY21	Q4 FY20	Gr %	FY21	FY20	Gr %
Revenue	431.0	301.7	42.9%	1,581.3	1,330.4	18.9%
Expenditure	309.0	244.4		1,145.0	986.8	
EBITDA	122.0	57.3	112.9%	436.3	343.6	27.0%
Adj for Stock Based Compensation & CSR cost	7.5	6.9		26.3	22.0	
Normalised EBITDA	129.5	64.2	101.7%	462.6	365.6	26.5%
<i>Normalised Margins</i>	30.0%	21.3%		29.3%	27.5%	
Other income	13.5	12.0		51.3	55.0	
PBT	110.8	45.4	144.1%	394.4	310.5	27.0%
<i>Margins</i>	25.7%	15.0%		24.9%	23.3%	
PAT	85.1	32.6	161.0%	296.5	227.6	30.3%
<i>Margins</i>	19.7%	10.8%		18.8%	17.1%	
EPS (Basic)	10.10	3.94	156.3%	35.33	27.42	28.8%
EPS (Diluted)	10.07	3.93	156.2%	35.25	27.37	28.8%



## About Dr. Lal PathLabs Limited

---

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2021 the company has 231 clinical laboratories (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 3,705 Patient Service Centers (PSCs) and 9,247 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

## Contact Details

---

Ved Prakash Goel  
Chief Financial Officer  
*Dr. Lal PathLabs Limited*

+91 124 3016500  
[cfo@lalpathlabs.com](mailto:cfo@lalpathlabs.com)

Mittali Bharti  
*Adfactors PR*

+91 9871154558  
[mittali.bharti@adfactorspr.com](mailto:mittali.bharti@adfactorspr.com)

For further information on Dr. Lal PathLabs see [www.lalpathlabs.com](http://www.lalpathlabs.com)

---

## Safe Harbour

---

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.